key: cord-0924956-kkhdkhze
authors: Freedberg, Daniel E.; Wang, Timothy C.; Abrams, Julian A.
title: Famotidine and COVID-19: Author Reply
date: 2021-01-13
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.01.013
sha: c1678e722631647c9177a2999500f715ef85df82
doc_id: 924956
cord_uid: kkhdkhze

nan

Singh et al. are interested in the formulation of famotidine received by patients in our study and whether there was concurrent antacid use. 1 In our retrospective study, 2 15% of patients who received famotidine during hospitalization for COVID-19 had home use of famotidine documented on the electronic medication reconciliation that must be performed at the time of hospital admission (compared to 1% of patients who did not receive famotidine during hospitalization for COVID-19, p<0.01). Accuracy of medication reconciliation can be poor, and 

What underlies the benefit of famotidine formulations used during COVID-19? Gastroenterology

Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study

Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19

Dual-histamine receptor blockade with cetirizine -famotidine reduces pulmonary symptoms in COVID-19 patients

Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series

Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized COVID-19 Patients from a Large Healthcare System

Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients